Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACET
SellSinkerAdicet Bio, Inc. · Healthcare · United States · $85M · Avg Vol: $880K/d
COMPANY DESCRIPTION
Adicet Bio, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic gamma delta T-cell therapies for cancer and autoimmune diseases. The company's proprietary platform engineers off-the-shelf gamma delta T-cells with chimeric antigen receptors (CARs) to enhance tumor targeting and durability. Adicet occupies a highly specialized niche in the cellular immunotherapy landscape, leveraging the innate and adaptive immune properties of gamma delta T-cells.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.0M | 0 | 0 | 0 | — | — | — | 28.5M | 2.7% |
| EPS | -7.81 | -15.32 | -21.28 | -16.95 | — | -10.42 | -6.36 | -4.04 | — |
| Shares | 9.3M | 9.3M | 5.2M | 9.6M | +2.6% | 9.4M | — | — | — |
| Debt | 21.0M | 20.9M | 17.2M | 14.7M | -11.2% | 12.9M | — | — | — |
| Equity | 292.3M | 170.2M | 186.6M | 159.2M | -18.3% | — | — | — | — |
| Op CF | -44.8M | -93.7M | -92.4M | -95.2M | — | -84.5M | — | — | — |
| Inv CF | -16.8M | -4.5M | -119.2M | 2.4M | — | — | — | — | — |
| Fin CF | 41.5M | 0.2M | 111.3M | 75.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACET are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACET | Adicet Bio, Inc.(you) | $85M | 22 | Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 25 | Sell |
| LONA | LeonaBio, Inc. | $75M | 20 | Strong Sell |
| MNOV | MediciNova, Inc. | $71M | 24 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 27 | Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| APLM | Apollomics, Inc. | $77M | 29 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 23 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%